Cancer Diagnosis in Patient Given LentiGlobin Revised to Severe Anemia

Cancer Diagnosis in Patient Given LentiGlobin Revised to Severe Anemia

292624

Cancer Diagnosis in Patient Given LentiGlobin Revised to Severe Anemia

A patient diagnosed initially with the blood cancer myelodysplastic syndrome (MDS) after receiving LentiGlobin, Bluebird Bio’s investigational gene therapy for sickle cell disease (SCD), now has a revised diagnosis of transfusion-dependent anemia, the company announced. A second patient who participated in the same study — the Phase 1/2 HGB-206 clinical trial (NCT02140554) — also was diagnosed with acute myeloid leukemia (AML), another type of a blood cancer. However, new analyses announced by the company last month…

You must be logged in to read/download the full post.